RO5093151

RO5093151 is a potent and highly selective small molecule inhibitor of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1), an enzyme involved in the conversion of inactive cortisone to active cortisol. Developed by Roche, this drug was investigated for its potential to reduce liver fat content in patients with non-alcoholic fatty liver disease (NAFLD) and for lowering intraocular pressure in patients with primary open angle glaucoma or ocular hypertension. Clinical studies demonstrated that RO5093151 effectively reduced liver fat and had a good safety profile at doses up to 200 mg twice daily for up to 12 weeks[2][3][5]. The mechanism of action involves inhibition of 11β-HSD1, thereby reducing local glucocorticoid activation[2][3].

Other names

11 Beta HSD inhibitor11-beta hydroxysteroid dehydrogenase inhibitor